跳至主要内容
临床试验/CTRI/2023/09/057176
CTRI/2023/09/057176尚未招募2 期

A randomized open-label pilot study to assess the pharmacoeconomic & therapeutic outcome in schizophrenia patients with aripiprazole regimen based on genetic polymorphism - NI

AJIITH XAVIER F0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Schizophrenia patients who will be started on aripiprazole therapy
  • 2.Patients >16 years of either gender
  • 3.Patient or legally authorized representative willing to give informed consent

排除标准

  • 1.Patients with chronic liver or kidney disease
  • 2.Pregnant and lactating females
  • 3. History of neurological, neuroendocrine, or other medical conditions known to affect the central nervous system.
  • 4. Any significant medical condition that has clinically significant interaction with aripiprazole

研究者

发起方
AJIITH XAVIER F

相似试验